Of 8 guidance figures from Quest Diagnostics's earnings releases that Stock Atlas has scored against the reported result, 8 came in above the guide, 0 in range and 0 below. It met or beat its own guidance 100% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Capital Expenditures | $500.00M | $527.00M | above |
| FY2025 | Revenue | $10.96B to $11.00B | $11.04B | above |
| FY2024 | Capital Expenditures | $420.00M | $425.00M | above |
| FY2024 | Revenue | $9.80B to $9.85B | $9.87B | above |
| FY2023 | Net revenues | $9.19B to $9.24B | $9.25B | above |
| FY2022 | Net revenues | $9.72B to $9.86B | $9.88B | above |
| FY2022 | Capital Expenditures | $400.00M | $404.00M | above |
| FY2021 | Net revenues | $10.45B to $10.60B | $10.79B | above |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Quest Diagnostics financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Quest Diagnostics (DGX) guidance record”, stockatlas.com/companies/DGX/guidance/, data as of 3 November 2026. Links to this page are welcome.
